Key facts
- This page summarizes Nancy Bryan's Form 4 filing for AIM ImmunoTech Inc. (AIMI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2025, 17:10.
Nancy Bryan - 14 Mar 2025 Form 4 Insider Report for AIM ImmunoTech Inc. (AIMI)
- Reporting relationship
- Director
- Issuer ticker
- AIMI
- Reported as of
- 14 Mar 2025
- Net transaction value
- +$5,208
- SEC form
- 4
- Accepted by SEC
- 18 Mar 2025, 17:10:33 UTC
- Prior SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nancy Bryan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Nancy Bryan filed Form 4 for AIM ImmunoTech Inc. (AIMI) on 18 Mar 2025.
Change
- Previous filing in this sequence was filed on 04 Mar 2025.
- Current net transaction value: +$5,208.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AIM
transaction
Common Stock
Award
- Transaction value
- $5,208
- Shares
- +44,899
- Change %
- +18%
- Price
- $0.1160
- Shares after
- 291,882
- Date
- 14 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares acquired on the Transaction Date were issued in lieu of director compensation pursuant to the issuer's Cash Conservation Plan.